Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Sep:230:108826.
doi: 10.1016/j.clim.2021.108826. Epub 2021 Aug 19.

Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin

Affiliations
Multicenter Study

Adverse reactions in a large cohort of patients with inborn errors of immunity receiving intravenous immunoglobulin

Hossein Esmaeilzadeh et al. Clin Immunol. 2021 Sep.

Abstract

Background: Intravenous immunoglobulins (IVIg) are the major treatment in inborn errors of immunity (IEI) disorders; However, IVIg infusions show some adverse effects. We aimed to assess the adverse reactions of IVIg infusions.

Methods: Data of IVIg infusions in IEI patients were collected from 2011 to 2021. Totally, 363 IEI patients received IVIg regularly in Iran entered the study. The adverse reactions are classified regarding their severity and chronicity.

Results: 22,667 IVIg infusions were performed in the study. 157 patients (43.2%) and 1349 (5.9%) infusions were associated with at least one type of adverse reaction. The highest rates of adverse reactions were seen in severe combined immunodeficiency. Myalgia, chills, headache, fever, and hypotension were the most frequent adverse effects of IVIg.

Conclusion: The reactions affect almost half of the patients mainly in the first infusions which necessitate the close observation of IEI patients receiving IVIg.

Keywords: Adverse reaction; Inborn errors of immunity; Intravenous immunoglobulins; Iran; Primary immunodeficiencies.

PubMed Disclaimer

Publication types

MeSH terms

Substances

LinkOut - more resources